PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II, developed specifically to study its central nervous system activity independent of melanocortin receptors in the skin. It acts as a non-selective melanocortin receptor agonist, with particular affinity for MC3R and MC4R subtypes located in the brain and spinal cord.
Research has examined PT-141 for its potential role in modulating sexual arousal pathways through central melanocortin signaling. Unlike compounds that act through vascular mechanisms, studies have focused on PT-141’s interactions with CNS pathways, particularly in the hypothalamus and limbic system areas associated with sexual motivation. Preclinical research in rodent models has examined its effects on sexually motivated behavior and arousal metrics.
Studies have also investigated PT-141’s potential interactions with dopamine release pathways, which may contribute to its observed effects in preclinical models. Researchers have examined its pharmacokinetic profile, noting a relatively longer duration of receptor engagement compared to some other melanocortin peptides. Clinical research programs have explored its potential applications, providing substantial pharmacological data.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
